Navigation Links
Novartis/Schering-Plough's Drug Will Replace AstraZeneca's Symbicort as Decision Resources' Clinical Gold Standard by 2012 for the Treatment of Asthma

A Therapy's Effect on Reduction of Exacerbations is the Attribute That Most Influences Physicians' Prescribing Decisions, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Novartis/Schering-Plough's indacaterol/mometasone will replace AstraZeneca's Symbicort as Decision Resources' proprietary clinical gold standard by 2012 for the treatment of asthma due to its once-daily dosing competitive advantage. In fact, because none of the therapies projected to launch within the next ten years are expected to offer advantages in efficacy over currently marketed long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations, Decision Resources' gold standard will be determined by incremental advantages in delivery, such as less-frequent daily dosing and a faster onset of action.

"Physicians we interviewed report that once-daily dosing has the potential to increase patient compliance. Patient compliance is important because asthma is a chronic disease that requires consistent administration of anti-inflammatory drugs to reduce disease severity and limit costly emergency healthcare," said Martin Quinn, analyst at Decision Resources.

The new report entitled Asthma: Emerging LABA/ICS Combinations Will Have a Difficult Time Differentiating Themselves from Existing Agents in the Class also finds that a therapy's effect on reducing exacerbations is the attribute that most influences physicians' prescribing decisions in asthma. Based on U.S. and European surveyed physicians, current and emerging therapies have no advantage over sales-leading GlaxoSmithKline's Advair/Seretide/Adoair on this attribute.

About the Report

Asthma: Emerging LABA/ICS Combinations Will Have a Difficult Time Differentiating Themselves from Existing Agents in the Class is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales              Elizabeth Marshall
    Decision Resources           Decision Resources, Inc.
    781-296-2691                 781-296-2563

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The next generation: nanomagnets could replace semiconductors
2. Carbon nanotubes to be replaced by MoSIx nanowires in high-tech devices says new study
3. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
4. The future of computing -- carbon nanotubes and superconductors to replace the silicon chip
5. Genomics Likely to Replace Traditional Drug Therapies in Treating CHF
6. NexGen Biofuels Ltd. Announces Plans to Replace its CFO With Local CFO
7. Half of Surveyed Physicians Expect to Replace Between 6 Percent and 15 Percent of Their Sustiva Prescriptions with Isentress
8. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
9. Facet Solutions Completes Facet Joint and Disc Replacement Study
10. Stenum Hospital Does its 600th American Disc Replacement Surgery
11. Cold atoms could replace hot gallium in focused ion beams
Post Your Comments:
(Date:11/24/2015)... ... , ... The Academy of Model Aeronautics (AMA), led by its Executive Council, ... Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing has ... type of racing and several new model aviation pilots have joined the community because ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation ... on being named to Deloitte's 2015 Technology Fast 500 list of the fastest ... AcceleDent®, a FDA-cleared, Class II medical device that speeds up orthodontic tooth movement ...
(Date:11/24/2015)... VILLAGE, Nev. , Nov. 24, 2015  PDL BioPharma, ... John P. McLaughlin , the company,s president and chief executive ... Jaffray Healthcare Conference next week in New York ... will occur on Tuesday, December 1, 2015 at 9:30 a.m. ... Presentations." Please connect to the website at least 15 minutes ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015  Vigilant Solutions announces today that Mr. ... of Directors. --> --> ... from the partnership at TPG Capital, one of the ... $140 Billion in revenue.  He founded and led TPG,s ... TPG companies, from 1997 to 2013.  In his first ...
(Date:11/16/2015)... SAN JOSE, Calif. , Nov 16, 2015 ... leading developer of human interface solutions, today announced ... new Synaptics TouchView ™ touch controller and ... the architectural revolution of smartphones. These new TDDI ... and include TD4100 (HD resolution), TD4302 (WQHD resolution), ...
(Date:11/12/2015)... Mass. , Nov. 12, 2015  Arxspan ... Institute of MIT and Harvard for use of ... discovery information management tools. The partnership will support ... both biological and chemical research information internally and ... will be used for managing the Institute,s electronic ...
Breaking Biology News(10 mins):